HRP20220419T1 - Terapija matičnim stanicama kod patologija endometrija - Google Patents
Terapija matičnim stanicama kod patologija endometrija Download PDFInfo
- Publication number
- HRP20220419T1 HRP20220419T1 HRP20220419TT HRP20220419T HRP20220419T1 HR P20220419 T1 HRP20220419 T1 HR P20220419T1 HR P20220419T T HRP20220419T T HR P20220419TT HR P20220419 T HRP20220419 T HR P20220419T HR P20220419 T1 HRP20220419 T1 HR P20220419T1
- Authority
- HR
- Croatia
- Prior art keywords
- isolated
- bmdscs
- subject
- use according
- bmdsc
- Prior art date
Links
- 230000002357 endometrial effect Effects 0.000 title claims 3
- 230000007170 pathology Effects 0.000 title 1
- 238000009168 stem cell therapy Methods 0.000 title 1
- 238000009580 stem-cell therapy Methods 0.000 title 1
- 210000005259 peripheral blood Anatomy 0.000 claims 3
- 239000011886 peripheral blood Substances 0.000 claims 3
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 2
- 210000001185 bone marrow Anatomy 0.000 claims 2
- 230000001483 mobilizing effect Effects 0.000 claims 2
- 210000000685 uterine artery Anatomy 0.000 claims 2
- 206010001928 Amenorrhoea Diseases 0.000 claims 1
- 206010055690 Foetal death Diseases 0.000 claims 1
- 206010021033 Hypomenorrhoea Diseases 0.000 claims 1
- 206010030295 Oligomenorrhoea Diseases 0.000 claims 1
- 238000002617 apheresis Methods 0.000 claims 1
- 210000002565 arteriole Anatomy 0.000 claims 1
- 230000032692 embryo implantation Effects 0.000 claims 1
- 238000002513 implantation Methods 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000008929 regeneration Effects 0.000 claims 1
- 238000011069 regeneration method Methods 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Thermotherapy And Cooling Therapy Devices (AREA)
Claims (11)
1. Izolirane autologne CD133+ matične stanice dobivene iz koštane srži (BMDSC) namijenjene upotrebi u poticanju regeneracije endometrija kod subjekta kojem je to potrebno, naznačene time što se izolirane CD133+ BMDSC primjenjuje u maternične arterije kod subjekta kojem je to potrebno.
2. Izolirane CD133+ BMDSC namijenjene upotrebi u skladu s patentnim zahtjevom 1, naznačene time što subjekt ima debljinu endometrija, u vrijeme ugnježđenja, manju od 5 mm.
3. Izolirane CD133+ BMDSC namijenjene upotrebi u skladu s bilo kojim od patentnih zahtjeva 1-2, naznačene time što subjekt ima amenoreju, hipomenoreju ili oligomenoreju.
4. Izolirane CD133+ BMDSC namijenjene upotrebi u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačene time što je subjekt imao ponavljane gubitke trudnoće.
5. Izolirane CD133+ BMDSC namijenjene upotrebi u skladu s bilo kojim od patentnih zahtjeva 1-4, naznačene time što je subjekt imao jedan ili više ranijih neuspjelih ugnježđenja embrija.
6. Izolirane CD133+ BMDSC namijenjene upotrebi u skladu s bilo kojim od patentnih zahtjeva 1-5, naznačene time što se izolirane autologne CD133+ BMDSC izoliralo iz periferne krvi kod subjekta nakon primjene na subjektu sredstva za mobiliziranje BMDSC iz koštane srži u perifernu krv kod subjekta.
7. Izolirane CD133+ BMDSC namijenjene upotrebi u skladu s bilo kojim od patentnih zahtjeva 1-6, naznačene time što je sredstvo za mobiliziranje BMDSC čimbenik stimuliranja kolonija granulocita (G-CSF).
8. Izolirane CD133+ BMDSC namijenjene upotrebi u skladu s bilo kojim od patentnih zahtjeva 6 ili 7, naznačene time što se autologne CD133+ BMDSC izolira iz perifernog krvotoka kod subjekta aferezom upotrebom protutijela protiv CD 133.
9. Izolirane CD133+ BMDSC namijenjene upotrebi u skladu s bilo kojim od patentnih zahtjeva 1-8, naznačene time što se CD133+ BMDSC primjenjuje u maternične arterije kroz kateter.
10. Izolirane CD133+ BMDSC namijenjene upotrebi u skladu s bilo kojim od patentnih zahtjeva 1-9, naznačene time što se CD133+ BMDSC primjenjuje u maternične spiralne arteriole kod subjekta.
11. Izolirane CD133+ BMDSC namijenjene upotrebi u skladu s bilo kojim od patentnih zahtjeva 1-10, naznačene time što se na subjektu primjenjuje najmanje 45 milijuna CD133+ BMDSC.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462013121P | 2014-06-17 | 2014-06-17 | |
| EP19169309.2A EP3569697B8 (en) | 2014-06-17 | 2015-06-05 | Stem cell therapy in endometrial pathologies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220419T1 true HRP20220419T1 (hr) | 2022-05-27 |
Family
ID=54329860
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240798TT HRP20240798T1 (hr) | 2014-06-17 | 2015-06-05 | Terapija matičnim stanicama kod patologija endometrija |
| HRP20220419TT HRP20220419T1 (hr) | 2014-06-17 | 2015-06-05 | Terapija matičnim stanicama kod patologija endometrija |
| HRP20191240 HRP20191240T1 (hr) | 2014-06-17 | 2019-07-11 | Terapija matičnim stanicama kod patologija endometrija |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240798TT HRP20240798T1 (hr) | 2014-06-17 | 2015-06-05 | Terapija matičnim stanicama kod patologija endometrija |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191240 HRP20191240T1 (hr) | 2014-06-17 | 2019-07-11 | Terapija matičnim stanicama kod patologija endometrija |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11129851B2 (hr) |
| EP (3) | EP4012023B1 (hr) |
| JP (2) | JP6920062B2 (hr) |
| CN (2) | CN107073040A (hr) |
| AU (1) | AU2015275798B2 (hr) |
| BR (1) | BR112016029558A2 (hr) |
| CA (1) | CA2952559C (hr) |
| CY (2) | CY1122615T1 (hr) |
| DK (2) | DK3158057T3 (hr) |
| ES (2) | ES2910306T3 (hr) |
| HR (3) | HRP20240798T1 (hr) |
| HU (2) | HUE058328T2 (hr) |
| LT (2) | LT3569697T (hr) |
| MX (1) | MX2016016756A (hr) |
| PL (3) | PL3569697T3 (hr) |
| PT (2) | PT3569697T (hr) |
| RS (3) | RS63093B1 (hr) |
| RU (1) | RU2725006C2 (hr) |
| SI (2) | SI3158057T1 (hr) |
| TR (1) | TR201910410T4 (hr) |
| WO (1) | WO2015193737A1 (hr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010010201A1 (es) | 2008-07-22 | 2010-01-28 | Equipo Ivi Investigacion Sl | Perfil de expresion genetica como marcador de la receptividad endometrial |
| JP6386450B2 (ja) | 2012-06-06 | 2018-09-05 | フンダシオ、インスティトゥト、デ、レセルカ、ビオメディカ（イエレベ、バルセロナ）Ｆｕｎｄａｃｉｏ Ｉｎｓｔｉｔｕｔ Ｄｅ Ｒｅｃｅｒｃａ Ｂｉｏｍｅｄｉｃａ （Ｉｒｂ Ｂａｒｃｅｌｏｎａ） | 肺がん転移の診断、予後診断および処置のための方法 |
| US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
| DK2906718T3 (da) | 2012-10-12 | 2019-07-01 | Inbiomotion Sl | Fremgangsmåde til diagnose, prognose og behandling af prostatakræftmetastase under anvendelse af c-maf |
| EP3272880B1 (en) | 2013-03-15 | 2020-11-25 | Fundació Institut de Recerca Biomèdica (IRB Barcelona) | Method for the diagnosis, prognosis and treatment of metastatic cancer |
| PT3569697T (pt) | 2014-06-17 | 2022-05-02 | Asherman Therapy S L | Terapia de células estaminais em patologias endometriais |
| EP3474866A4 (en) * | 2016-06-23 | 2020-02-26 | Tithon Biotech, Inc. | CELLS EXPRESSING THE PARATHYROID HORMONE RECEPTOR 1 AND USES THEREOF |
| RU2699029C1 (ru) * | 2018-12-10 | 2019-09-03 | Частное образовательное учреждение дополнительного профессионального образования "Академия медицинского образования имени Федора Ивановича Иноземцева" (ЧОУ ДПО "Академия медицинского образования им. Ф.И. Иноземцева") | Способ использования мезенхимальных стволовых клеток для улучшения состояния рубца на матке |
| RU2741621C1 (ru) * | 2020-09-25 | 2021-01-28 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Федерации | Способ лечения внутриматочных синехий |
| CN117979980A (zh) | 2021-07-23 | 2024-05-03 | 车医科学大学校产学协力团 | 用于预防或治疗阿谢曼综合征的包含分离的线粒体作为活性成分的药物组合物 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR920700648A (ko) | 1989-05-05 | 1992-08-10 | 오닐 크리스토퍼 | 가임성 향상 |
| US6979533B2 (en) | 1992-06-12 | 2005-12-27 | The Trustees Of The University Of Pennsylvania | Determination of endometrial receptivity toward embryo implantation |
| CA2203718A1 (en) | 1997-04-25 | 1998-10-25 | University Of British Columbia | Cadherin-11 as an indicator of viable pregnancy |
| IL127896A0 (en) | 1998-12-31 | 1999-10-28 | Gail Laster | A novel treatment for preeclampsia and related diseases |
| WO2001066786A1 (en) | 2000-03-08 | 2001-09-13 | Kliman Harvey J | Methods of diagnosing and monitoring endometrial glandular development |
| AU2001264900A1 (en) | 2000-05-24 | 2001-12-03 | Schering Aktiengesellschaft | Pharmaceutical use of fibulin-1 |
| US6780594B2 (en) | 2000-09-25 | 2004-08-24 | Schering Aktiengesellschaft | Method for in vitro diagnosis of endometriosis |
| AUPR673001A0 (en) | 2001-07-31 | 2001-08-23 | Prince Henry's Institute Of Medical Research | Pregnancy-related enzyme activity |
| DE10139874A1 (de) | 2001-08-10 | 2003-04-30 | Schering Ag | Humane Mater-Proteine |
| GB0201284D0 (en) | 2002-01-21 | 2002-03-06 | Isis Innovation | Screening methods for contraceptive and fertility agents |
| US20030186300A1 (en) | 2002-03-20 | 2003-10-02 | Ali Akoum | Methods and products for modulation of reproductive processes and for diagnosis, prognostication and treatment of related conditions |
| WO2004061074A2 (en) | 2002-05-14 | 2004-07-22 | The Board Of Trustees Of The Leland Stanford Junior University | Endometrial genes in endometrial disorders |
| AU2003255355A1 (en) | 2002-08-02 | 2004-02-25 | Schering Aktiengesellschaft | Progesterone receptor modulators having an increased antigonadotropic activity for use in female fertility testing and hormone replacement therapy |
| DE10236405A1 (de) | 2002-08-02 | 2004-02-19 | Schering Ag | Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie |
| WO2004058999A2 (de) | 2002-12-21 | 2004-07-15 | Universität Leipzig | Verfahren und mittel zur bestimmung von bestimmten zuständen bzw. veränderungen im uterusepithel und im epithel anderer organe |
| WO2005018796A1 (en) | 2003-08-21 | 2005-03-03 | Pamgene B.V. | Microarray support for bioprobe synthesis |
| CN1863905A (zh) | 2003-09-08 | 2006-11-15 | 得克萨斯系统大学董事会 | 通过用前列腺素或前列腺素类似物补充培养基加强体外胚发育的方法以及组合物 |
| WO2005026324A2 (en) | 2003-09-08 | 2005-03-24 | The Board Of Regents Of The University Of Texas System | Method and composition for enhancing in vitro embryo development by supplementing culture medium with prostaglandin or a prostaglandin analog |
| AU2004303448A1 (en) | 2003-12-23 | 2005-07-07 | Mount Sinai Hospital | Methods for detecting markers associated with endometrial disease or phase |
| JP2008501035A (ja) | 2004-05-28 | 2008-01-17 | アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ | 妊孕性関連障害の治療におけるｉｌ−１７の使用 |
| RU2434645C2 (ru) * | 2006-03-31 | 2011-11-27 | Конинклейке Филипс Электроникс, Н.В. | Системы и методы измерения клеток, использующие ультракороткую т2*-релаксометрию |
| JP2007278750A (ja) | 2006-04-04 | 2007-10-25 | Ono Pharmaceut Co Ltd | プロスタグランジン類及びその類縁体の定量方法 |
| WO2008036374A2 (en) * | 2006-09-21 | 2008-03-27 | Medistem Laboratories, Inc. | Allogeneic stem cell transplants in non-conditioned recipients |
| GB0703683D0 (en) * | 2007-02-26 | 2007-04-04 | Ark Therapeutics Ltd | The treatment of complications in pregnancy |
| US9259233B2 (en) * | 2007-04-06 | 2016-02-16 | Hologic, Inc. | Method and device for distending a gynecological cavity |
| WO2009143633A1 (en) | 2008-05-30 | 2009-12-03 | Institut De Recherches Cliniques De Montreal | Pcsk9 inhibitors and methods of use thereof |
| WO2010010201A1 (es) | 2008-07-22 | 2010-01-28 | Equipo Ivi Investigacion Sl | Perfil de expresion genetica como marcador de la receptividad endometrial |
| WO2013166281A1 (en) * | 2012-05-02 | 2013-11-07 | Cedars-Sinai Medical Center | Bi-functional compositions for targeting cells to diseased tissues and methods of using same |
| EP2348318A1 (en) | 2010-01-21 | 2011-07-27 | Equipo Ivi Investigación, S.L. | Diagnostic method for endometrial receptivity |
| PT2768976T (pt) | 2011-10-21 | 2018-04-05 | Inst Nat Sante Rech Med | Métodos para avaliar a receptividade endométrica de uma paciente após hiperestimulação ovárica controlada |
| WO2013081554A1 (en) | 2011-11-30 | 2013-06-06 | Agency For Science, Technology And Research | Gm1 ganglioside to annexin v microparticle polypeptide ratio for biological monitoring |
| EP2867670B1 (en) | 2012-06-27 | 2018-05-30 | Roche Diagnostics GmbH | MEANS AND METHODS APPLYING sFlt-1/PlGF OR ENDOGLIN/PlGF RATIO TO RULE-OUT ONSET OF PREECLAMPSIA WITHIN A CERTAIN TIME PERIOD |
| RU2515475C1 (ru) * | 2012-11-15 | 2014-05-10 | Федеральное государственное бюджетное учреждение науки ИНСТИТУТ ЦИТОЛОГИИ РОССИЙСКОЙ АКАДЕМИИ НАУК | Способ стимуляции образования децидуальной оболочки эндометрия в эксперименте |
| CN106662589B (zh) | 2014-03-21 | 2019-07-30 | 艾基诺米公司 | 先兆子痫的早期检测 |
| PT3569697T (pt) | 2014-06-17 | 2022-05-02 | Asherman Therapy S L | Terapia de células estaminais em patologias endometriais |
-
2015
- 2015-06-05 PT PT191693092T patent/PT3569697T/pt unknown
- 2015-06-05 RU RU2017101147A patent/RU2725006C2/ru active
- 2015-06-05 BR BR112016029558A patent/BR112016029558A2/pt not_active Application Discontinuation
- 2015-06-05 MX MX2016016756A patent/MX2016016756A/es active IP Right Grant
- 2015-06-05 AU AU2015275798A patent/AU2015275798B2/en active Active
- 2015-06-05 RS RS20220339A patent/RS63093B1/sr unknown
- 2015-06-05 US US15/318,825 patent/US11129851B2/en active Active
- 2015-06-05 SI SI201530822T patent/SI3158057T1/sl unknown
- 2015-06-05 RS RS20240690A patent/RS65719B1/sr unknown
- 2015-06-05 LT LTEP19169309.2T patent/LT3569697T/lt unknown
- 2015-06-05 DK DK15781411.2T patent/DK3158057T3/da active
- 2015-06-05 HR HRP20240798TT patent/HRP20240798T1/hr unknown
- 2015-06-05 JP JP2016573587A patent/JP6920062B2/ja active Active
- 2015-06-05 PL PL19169309T patent/PL3569697T3/pl unknown
- 2015-06-05 PL PL15781411T patent/PL3158057T3/pl unknown
- 2015-06-05 CN CN201580043147.1A patent/CN107073040A/zh active Pending
- 2015-06-05 ES ES19169309T patent/ES2910306T3/es active Active
- 2015-06-05 HR HRP20220419TT patent/HRP20220419T1/hr unknown
- 2015-06-05 SI SI201531822T patent/SI3569697T1/sl unknown
- 2015-06-05 EP EP22150013.5A patent/EP4012023B1/en active Active
- 2015-06-05 HU HUE19169309A patent/HUE058328T2/hu unknown
- 2015-06-05 RS RSP20190913 patent/RS59210B1/sr unknown
- 2015-06-05 PT PT15781411T patent/PT3158057T/pt unknown
- 2015-06-05 HU HUE15781411 patent/HUE044823T2/hu unknown
- 2015-06-05 PL PL22150013.5T patent/PL4012023T3/pl unknown
- 2015-06-05 LT LTEP15781411.2T patent/LT3158057T/lt unknown
- 2015-06-05 DK DK19169309.2T patent/DK3569697T3/da active
- 2015-06-05 CN CN202310575540.1A patent/CN116747241A/zh active Pending
- 2015-06-05 ES ES15781411T patent/ES2736117T3/es active Active
- 2015-06-05 CA CA2952559A patent/CA2952559C/en active Active
- 2015-06-05 EP EP15781411.2A patent/EP3158057B1/en active Active
- 2015-06-05 EP EP19169309.2A patent/EP3569697B8/en active Active
- 2015-06-05 TR TR2019/10410T patent/TR201910410T4/tr unknown
- 2015-06-05 WO PCT/IB2015/001715 patent/WO2015193737A1/en active Application Filing
-
2019
- 2019-07-11 HR HRP20191240 patent/HRP20191240T1/hr unknown
- 2019-07-16 CY CY20191100753T patent/CY1122615T1/el unknown
-
2020
- 2020-06-12 JP JP2020102340A patent/JP2020138984A/ja active Pending
-
2022
- 2022-04-05 CY CY20221100258T patent/CY1125938T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220419T1 (hr) | Terapija matičnim stanicama kod patologija endometrija | |
| DOP2017000186A (es) | Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes | |
| CL2018000353A1 (es) | Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes | |
| MY196631A (en) | Antibody Agents Specific for Human Cd19 and uses Thereof | |
| JP2015131795A5 (hr) | ||
| EA201890725A1 (ru) | Агонисты фарнезоидного х-рецептора и их применение | |
| AR105433A1 (es) | Métodos para mejorar la eficacia y expansión de las células inmunes | |
| CO6640274A2 (es) | Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes | |
| JOP20170004B1 (ar) | الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته | |
| UY33047A (es) | Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes | |
| JP2017522288A5 (hr) | ||
| HN2011001195A (es) | Compuestos que expanden las celulas madre hematopoieticas | |
| CR20190247A (es) | Métodos para el tratamiento de la atrofia muscular y enfermedad ósea con el uso de proteínas trap híbridas novedosas del ligando actriib | |
| CL2016000063A1 (es) | Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen. | |
| JOP20200231A1 (ar) | ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها | |
| CL2018000565A1 (es) | Compuestos derivados de piridinona dicarboxamida, inhibidores de bromodominio; composicion farmaceutica; combinacion farmaceutica; utiles en el tratamiento de enfermedades autoinmunitarias, inflamatorias, virales y cancer, entre otras. | |
| AR101476A1 (es) | Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk) | |
| CR20160131A (es) | Formulaciones de (s)-3-(4- ((4- (morfolinometil)benzil) oxi) -1-oxoisoindolin)-2-il) piperidin -2,6-diona | |
| EP3641811A4 (en) | IMMUNPRIVILEGATED BIOACTIVE KIDNEY CELLS FOR TREATMENT OF KIDNEY DISEASE | |
| BR112017005713A2 (pt) | composto da fórmula (i), método de mobilização das células-tronco hematopoiéticas (hsc) e células progenitoras endoteliais (epc) na circulação periférica, método de tratamento de lesão tecidual, câncer, doença inflamatória ou doença autoimune, e composição farmacêutica | |
| EA201591345A1 (ru) | Способы лечения фиброза и рака | |
| EA201692126A1 (ru) | Способ достижения безлекарственной ремиссии у субъектов с ранним ревматоидным артритом (ra, ра) | |
| WO2015120436A3 (en) | Stat3 phosphorylation during graft-versus-host disease | |
| MX2021003798A (es) | Terapia con celulas de placenta humana y celulas hematopoyeticas. | |
| CL2015002971A1 (es) | Composición biofarmacológica que comprende componentes producidos y/o secretados por células troncales mesenquimales (msc), que permite recuperar la capacidad regenerativa tisular, en una situación de esteatosis hepática, o donde la capacidad de regeneración endógena del tejido hepático se encuentra inhibida |